thiamine derivatives
Summary
Ordinary thiamine is a charged molecule that relies on saturable transporters to cross membranes. Beginning in the 1950s, mainly in Japan, chemists developed thiamine derivatives designed to be absorbed more efficiently. Almost all of them share one chemical trick: they are versions of thiamine in which the thiazolium ring has been opened and "locked" by attaching a group to the sulfur atom. This removes the permanent positive charge. Once inside the body, the lock is removed, the ring closes and ordinary thiamine is released.
Derivatives reliably produce higher blood thiamine levels than equivalent amounts of thiamine salts. They differ from each other in chemistry, in where they deliver thiamine (for example, whether they raise brain levels), and possibly in effects that are not explained by thiamine delivery alone. Clinical evidence varies from reasonable (some benfotiamine trials) to very limited or absent (several newer or less-studied compounds).
Why derivatives were developed
Saturable absorption: at dietary doses, thiamine uptake depends on the THTR-1 and THTR-2 transporters (see Thiamine Transporters).
Beriberi in Japan: a long history of thiamine deficiency drove Japanese research into better-absorbed forms.
A natural lead: in the early 1950s, Motonori Fujiwara and colleagues in Kyoto found that thiamine reacts with allicin from garlic to form allithiamine, a lipid-soluble disulfide that was better absorbed than thiamine. This discovery launched the development of synthetic analogues.
The key chemical idea
Classes and main compounds
Allithiamine
Disulfide
Thiamine allyl disulfide
Natural (garlic and Allium species); discovered early 1950s
Prosultiamine (thiamine propyl disulfide, TPD)
Disulfide
Propyl disulfide analogue
Synthetic, Japan
Fursultiamine (TTFD)
Disulfide
Thiamine tetrahydrofurfuryl disulfide
Synthetic, Japan, 1960s
Sulbutiamine
Disulfide (dimer)
Two O-isobutyryl thiamine units joined by a disulfide
Synthetic, Japan
Bisbentiamine
Disulfide (dimer)
O-benzoyl thiamine disulfide
Synthetic, Japan
Thiamine disulfide
Disulfide (dimer)
Two open-form thiamine molecules linked by S–S
Natural oxidation product; also used as a drug
Benfotiamine
S-acyl (thioester) with phosphate
S-benzoylthiamine O-monophosphate
Synthetic, Japan, late 1950s
Dibenzoylthiamine (DBT)
O,S-diacyl (thioester + ester)
O,S-dibenzoylthiamine
Synthetic, Japan; renewed research interest since ~2020
Cetotiamine
O,S-diacyl (carbonate)
O,S-diethoxycarbonylthiamine
Synthetic, Japan
Cycotiamine (cyclocarbothiamine)
Cyclic thiocarbonate
Open-form thiamine with sulfur and oxygen joined in a 1,3-oxathian-2-one ring
Synthetic, Japan, 1960s
Comparative pharmacology
Thiamine salts
Carrier-mediated at low doses; diffusion at high doses
Baseline comparator
Regulated by transporters
See Thiamine Salts & Forms
Benfotiamine
Dephosphorylated in the gut to lipophilic S-benzoylthiamine, then absorbed
Highest of the compounds compared in human studies
Little or no increase in mice
Not lipid-soluble itself; poorly soluble in water and organic solvents
Fursultiamine (TTFD)
Lipophilic; passive diffusion
Higher than thiamine salts
Increases reported
Garlic-like odour
Sulbutiamine
Highly lipophilic
Higher than thiamine salts
Increases thiamine and phosphate esters in rat brain
Developed for central effects
Dibenzoylthiamine
Lipophilic
Higher than thiamine in mice
Data limited
Mainly preclinical
In a human crossover study comparing oral derivatives, benfotiamine produced the highest plasma and erythrocyte thiamine levels, followed by fursultiamine, and then thiamine disulfide.
Beyond thiamine delivery
Several studies, mainly in cells and rodents, report that thioester derivatives (benfotiamine and dibenzoylthiamine) have antioxidant and anti-inflammatory effects that do not appear to be explained by increases in TPP or TPP-dependent enzyme activity. Proposed explanations include:
activation of the Nrf2 antioxidant pathway;
effects of as-yet-unidentified open-thiazole-ring metabolites;
modulation of signalling enzymes such as GSK-3β.
These mechanisms are preclinical hypotheses. The active metabolites have not been identified.
Clinical evidence at a glance
Benfotiamine
Several randomized controlled trials (diabetic neuropathy, nephropathy, Alzheimer's disease); a larger Alzheimer's trial is under way
Fursultiamine (TTFD)
Small open-label studies; long clinical use in Japan
Sulbutiamine
Older trials in fatigue (asthenia); small open-label studies
Prosultiamine
Small open-label trial in HTLV-1-associated myelopathy
Dibenzoylthiamine
No published controlled human trials found as of October 2026
Others
Little modern published research
Safety overview
Thiamine derivatives have generally been well tolerated in published studies, including benfotiamine for up to 12–24 months.
Long-term safety data are much more limited than for thiamine itself, especially for sulbutiamine and dibenzoylthiamine.
Disulfides release thiol by-products (for example, tetrahydrofurfuryl mercaptan from TTFD), which can cause a garlic-like odour.
Regulatory status varies: some derivatives are licensed medicines in some countries and sold as supplements in others.
Pages in this section
Benfotiamine
Thiamine Tetrahydrofurfuryl Disulfide (TTFD)
Dibenzoylthiamine (DBT)
Sulbutiamine
Novel Derivatives & Future Research
Open questions
Which derivative, if any, best delivers thiamine to the human brain?
Which effects are due to thiamine delivery, and which to other metabolites?
How do derivatives compare head-to-head on clinical outcomes? Such trials are almost entirely lacking.
What are the long-term safety profiles of the less-studied compounds?
Related pages
Thiamine Structure
Thiamine Transporters
Mechanisms of Malabsorption
Common Misconceptions
References
Fujiwara M. Allithiamine and its properties. Journal of Nutritional Science and Vitaminology. 1976;22(Suppl):57–62.
Lonsdale D. Thiamine tetrahydrofurfuryl disulfide: a little known therapeutic agent. Medical Science Monitor. 2004;10(9):RA199–RA203.
Bitsch R, et al. Bioavailability assessment of the lipophilic benfotiamine as compared to a water-soluble thiamin derivative. Annals of Nutrition and Metabolism. 1991;35(5):292–296.
Greb A, Bitsch R. Comparative bioavailability of various thiamine derivatives after oral administration. International Journal of Clinical Pharmacology and Therapeutics. 1998;36(4):216–221.
Volvert ML, et al. Benfotiamine, a synthetic S-acyl thiamine derivative, has different mechanisms of action and a different pharmacological profile than lipid-soluble thiamine disulfide derivatives. BMC Pharmacology. 2008;8:10.
Bettendorff L, et al. Injectable sulbutiamine induces an increase in thiamine concentrations and thiamine phosphate esters in rat brain. Biochemical Pharmacology. 1990;40(11):2557–2560.
Sambon M, Wins P, Bettendorff L. Neuroprotective effects of thiamine and precursors with higher bioavailability: focus on benfotiamine and dibenzoylthiamine. International Journal of Molecular Sciences. 2021;22(11):5418.
[Authors to be confirmed]. Synthetic thioesters of thiamine: promising tools for slowing progression of neurodegenerative diseases. International Journal of Molecular Sciences. 2023;24(14):11296.
Nakamura T, et al. Efficacy of prosultiamine treatment in patients with human T lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis: results from an open-label clinical trial. BMC Medicine. 2013;11:182.
Was this helpful?

